KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to ixazomib. In this study we examined factors respo...
Saved in:
| Main Authors: | Nibedita Chattopadhyay, Allison J Berger, Erik Koenig, Bret Bannerman, James Garnsey, Hugues Bernard, Paul Hales, Angel Maldonado Lopez, Yu Yang, Jill Donelan, Kristen Jordan, Stephen Tirrell, Bradley Stringer, Cindy Xia, Greg Hather, Katherine Galvin, Mark Manfredi, Nelson Rhodes, Ben Amidon |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144825&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ixazomib-associated skin exfoliation
by: Yali Zhang, et al.
Published: (2022-04-01) -
Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib
by: Suheil Albert Atallah-Yunes, et al.
Published: (2018-01-01) -
Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01) -
Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis
by: Aaron S. Rosenberg, et al.
Published: (2025-08-01) -
Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)